je.st

Home › enter collaboration

Tag: enter collaboration

Eisai And Biogen Idec Enter Collaboration To Develop And Commercialize Alzheimer's Disease Treatments

2014-03-05 05:29:31| drugdiscoveryonline News Articles

Eisai Co., Ltd. and Biogen Idec recently announced that they have entered into a collaboration to develop and commercialize two of Eisai’s clinical candidates for Alzheimer’s disease (AD), E2609 and BAN2401

Tags: enter develop disease collaboration

Merck and Samsung Bioepis Enter Collaboration Agreement to Develop and Commercialize Insulin Glargine Candidate for Diabetes

2014-02-10 14:43:00| Merck.com - Corporate News

Dateline City: WHITEHOUSE STATION, N.J. & SEOUL, SOUTH KOREA WHITEHOUSE STATION, N.J. & SEOUL, SOUTH KOREA--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, and Samsung Bioepis Co., Ltd., announced today that they have expanded their collaboration with an agreement to develop, manufacture and commercialize MK-1293, an insulin glargine candidate for the treatment of patients with type 1 and type 2 diabetes. Phase III clinical studies in type 1 and type 2 diabetes will begin soon. Language: English Contact: Merck Media InquiriesKim Hamilton, 908-423-6831orCaroline Lappetito, 267-305-7639orMerck Investor RelationsCarol Ferguson, 908-423-4465orSamsung Media InquiriesHongSeok Ji, +82-32-455-6102orSamsung Investor RelationsSungjoon Park, +82-32-455-6120 Ticker Slug: Ticker: MRK Exchange: NYSE read more

Tags: for enter agreement develop

Muhlbauer, NovaCentrix enter collaboration

2013-04-30 17:55:00| Label and Narrow Web Breaking News

The companies will team up to offer new RFID antenna manufacturing technology.

Tags: enter collaboration enter collaboration

Merck & Co., Inc. and Pfizer Enter Worldwide Collaboration Agreement to Develop and Commercialize Ertugliflozin, an Investigational Medicine for Type 2 Diabetes

2013-04-29 13:30:00| Merck.com - Research & Development News

Dateline City: WHITEHOUSE STATION, N.J. & NEW YORK WHITEHOUSE STATION, N.J. & NEW YORK--(BUSINESS WIRE)--Merck & Co., Inc. (NYSE: MRK), known as MSD outside the United States and Canada (Merck), and Pfizer Inc. (NYSE:PFE) today announced that they have entered into a worldwide (except Japan) collaboration agreement for the development and commercialization of Pfizers ertugliflozin (PF-04971729), an investigational oral sodium glucose cotransporter (SGLT2) inhibitor being evaluated for the treatment of type 2 diabetes. Language: English Contact HTML: Merck Media Relations:Steven Cragle: (908) 423-3461Kim Hamilton: (908) 423-6831orPfizer Media Relations:Joan Campion: (212) 733-2798orMerck Investor Relations:Carol Ferguson: (908) 423-4465Justin Holko: (908) 423-5088orPfizer Investor Relations:Chuck Triano: (212) 733-3901 Ticker Slug: Ticker: MRK Exchange: NYSE Ticker: PFE Exchange: NYSE read more

Tags: for type enter agreement